Please assess the completion status of the following clinical trial:

Trial Title: DE-111 Against Timolol Ophthalmic Solution 0.5%

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary open angle glaucoma or ocular hypertension~* Provided signed, written informed consent~* 20 years of age and older~* If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study~Exclusion Criteria:~* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception~* Presence of any abnormality or significant illness that could be expected to interfere with the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- DE-111 ophthalmic solution (Type: EXPERIMENTAL): DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
- Timolol ophthalmic solution 0.5% (Type: ACTIVE_COMPARATOR): Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.

Based on this trial design, predict the completion outcome and termination type (if applicable).